Tempest Therapeutics Financial Summary for Q3
On November 5, 2025, Tempest Therapeutics, Inc. (Nasdaq: TPST), a pioneering biotechnology firm focused on developing targeted and immune-mediated therapies for cancer, announced its financial results for the third quarter ended September 30, 2025.
In a statement from Stephen Brady, the company’s president and CEO, he emphasized their ongoing strategic alternatives process aimed at enhancing shareholder value. He also expressed optimism about the upcoming Phase 2 trial of TPST-1495, collaborating with the National Cancer Institute (NCI) and the Cancer Prevention Clinical Trials Network. This trial is believed to have the potential to significantly benefit patients with hepatocellular carcinoma (HCC).
Third Quarter Financial Highlights
During the third quarter, Tempest's financials reflected significant shifts in cash positions and expenses:
- Cash and cash equivalents stood at $7.5 million, down from $30.3 million at the end of 2024. This reduction was primarily attributed to operational expenditures, which were somewhat mitigated by net proceeds from recent capital raises totaling $6.9 million.
- The company reported a net loss of $3.5 million, translating to a net loss per share of $0.79. This is a marked improvement from the $10.6 million loss and $5.32 loss per share experienced during the same quarter in 2024.
- Research and development (R&D) costs plunged to $0.6 million, starkly reduced from $7.6 million in the previous year, as strategic focuses shifted.
- General and administrative expenses held steady at $3.0 million, consistent with last year, reflecting ongoing costs primarily in consulting and professional services.
Year-to-Date Performance
Looking at the nine-month period ending September 30, 2025, the financial performance showed notable trends:
- Cash utilization for operations reached $23.2 million, presenting the ongoing need for strategic financial management.
- The net loss for this period amounted to $22.2 million, or $5.71 per share, down from $28.0 million and $15.48 per share in the comparable period of 2024.
- R&D expenditures for the year totaled $12.1 million, which reflects prior year expenditures of $17.7 million, demonstrating a focused reduction in spending as strategic alternatives were explored.
- General and administrative expenses remained unchanged at $10.4 million year-over-year, primarily driven by compensation and consulting costs associated with the workforce adjustments made earlier this year.
About Tempest Therapeutics
Tempest Therapeutics stands at the forefront of cancer treatment innovation, developing a diverse array of small molecule candidates aimed at tackling various tumors through either tumor-targeted or immune-based mechanisms. The company prides itself on its rigorous approach to clinical research and patient care.
Future Prospects
As Tempest continues its strategic evaluation, there is a palpable sense of optimism regarding its clinical programs and financial stewardship. The management's commitment to enhancing shareholder value through thoughtful strategy execution remains unwavering.
Frequently Asked Questions
1. What is Tempest Therapeutics’ main focus?
Tempest Therapeutics primarily focuses on developing innovative cancer therapies through targeted and immune-mediated approaches.
2. How did Tempest’s financial position change in Q3 2025?
Tempest saw a decline in cash reserves to $7.5 million, reflecting operational expenditures and strategic investments.
3. What collaborations does Tempest Therapeutics have?
Tempest is currently collaborating with the NCI and the Cancer Prevention Clinical Trials Network on its TPST-1495 Phase 2 trial.
4. How has Tempest’s loss per share changed compared to last year?
The loss per share improved to $0.79 in Q3 2025 compared to $5.32 in Q3 2024, signaling better cost management.
5. What are Tempest's future plans regarding strategic alternatives?
The company is actively engaged in pursuing strategic alternatives aimed at maximizing value for shareholders while advancing its clinical development programs.
